CA2388314A1 - Imidazole derivatives as phosphodiesterase vii inhibitors - Google Patents

Imidazole derivatives as phosphodiesterase vii inhibitors Download PDF

Info

Publication number
CA2388314A1
CA2388314A1 CA002388314A CA2388314A CA2388314A1 CA 2388314 A1 CA2388314 A1 CA 2388314A1 CA 002388314 A CA002388314 A CA 002388314A CA 2388314 A CA2388314 A CA 2388314A CA 2388314 A1 CA2388314 A1 CA 2388314A1
Authority
CA
Canada
Prior art keywords
imidazole derivatives
phosphodiesterase vii
vii inhibitors
relates
hal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002388314A
Other languages
French (fr)
Other versions
CA2388314C (en
Inventor
Michael Eggenweiler
Jonas Rochus
Michael Wolf
Michael Gassen
Oliver Poschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2388314A1 publication Critical patent/CA2388314A1/en
Application granted granted Critical
Publication of CA2388314C publication Critical patent/CA2388314C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)

Abstract

The invention relates to imidazole derivatives of formula (I), wherein R1 means H, A, benzyl, indane-5-yl, 1,2,3,4-tetrahydro-naphthaline-5-yl, dibenzothiophene-2-yl or phenyl that is unsubstituted or substituted once, twice or three times by means of Hal, A, A-CO-NH, benzyloxy, alkoxy, COOH or COOA, R2 means H or A, X means O or S, Hal means F, Cl, Br or I and A means alkyl with 1 to 6 C-atoms. The invention also relates to the physiologically acceptable salts and/or solvates thereof acting as phosphodiesterase VII
inhibitors. The invention further relates to the use thereof for producing a medicament.
CA002388314A 1999-10-21 2000-10-10 Imidazole derivatives as phosphodiesterase vii inhibitors Expired - Fee Related CA2388314C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19950647A DE19950647A1 (en) 1999-10-21 1999-10-21 Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS
DE19950647.7 1999-10-21
PCT/EP2000/009926 WO2001029049A2 (en) 1999-10-21 2000-10-10 Imidazole derivatives as phosphodiesterase vii inhibitors

Publications (2)

Publication Number Publication Date
CA2388314A1 true CA2388314A1 (en) 2001-04-26
CA2388314C CA2388314C (en) 2009-06-16

Family

ID=7926352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388314A Expired - Fee Related CA2388314C (en) 1999-10-21 2000-10-10 Imidazole derivatives as phosphodiesterase vii inhibitors

Country Status (22)

Country Link
EP (1) EP1222193B1 (en)
JP (1) JP2003512381A (en)
KR (1) KR20020060201A (en)
CN (1) CN1382146A (en)
AR (1) AR026198A1 (en)
AT (1) ATE247121T1 (en)
AU (1) AU780788B2 (en)
BR (1) BR0014922A (en)
CA (1) CA2388314C (en)
CZ (1) CZ293751B6 (en)
DE (2) DE19950647A1 (en)
DK (1) DK1222193T3 (en)
ES (1) ES2200957T3 (en)
HU (1) HUP0203139A3 (en)
MX (1) MXPA02003952A (en)
NO (1) NO20021846L (en)
PL (1) PL355020A1 (en)
PT (1) PT1222193E (en)
RU (1) RU2259199C2 (en)
SK (1) SK4922002A3 (en)
WO (1) WO2001029049A2 (en)
ZA (1) ZA200203995B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0207215B8 (en) 2001-12-13 2022-11-01 Daiichi Suntory Biomedical Res Limited PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7 INHIBITING ACTION
DE10163991A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
JP2006219374A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Imidazotriazinone derivative having pde 7 inhibition
JP2006219373A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pyridinylpyrazolopyrimidinone derivative having pde 7 inhibition
DK2433943T3 (en) 2004-07-01 2013-12-16 Daiichi Sankyo Co Ltd Intermediates for thienopyrazole derivatives with PDE7 inhibitory activity
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
BRPI0809244A2 (en) 2007-03-27 2014-09-23 Omeros Corp METHODS OF TREATMENT OF A MOVEMENT ABNORMALITY, AND FOR IDENTIFYING AN AGENT INHIBITING PDE7 ACTIVITY.
AU2011326173B2 (en) 2010-11-08 2015-08-27 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305954A (en) * 1981-02-11 1981-12-15 E. I. Du Pont De Nemours And Company Antiinflammatory 3,4-dihydro(or 1,4-dihydro)-2-[(substituted)thio]-[1]benzopyrano[3,4-d]imidazoles and their corresponding sulfoxides and sulfones
EP1146888A2 (en) * 1998-10-15 2001-10-24 BioImage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targetting
AU4589800A (en) * 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors

Also Published As

Publication number Publication date
ATE247121T1 (en) 2003-08-15
DE19950647A1 (en) 2001-04-26
CZ20021251A3 (en) 2002-07-17
WO2001029049A3 (en) 2001-11-01
EP1222193A2 (en) 2002-07-17
SK4922002A3 (en) 2002-09-10
NO20021846D0 (en) 2002-04-19
AU1135601A (en) 2001-04-30
WO2001029049A2 (en) 2001-04-26
PL355020A1 (en) 2004-03-22
AR026198A1 (en) 2003-01-29
EP1222193B1 (en) 2003-08-13
PT1222193E (en) 2003-12-31
MXPA02003952A (en) 2004-09-06
JP2003512381A (en) 2003-04-02
CA2388314C (en) 2009-06-16
ES2200957T3 (en) 2004-03-16
DK1222193T3 (en) 2003-12-01
AU780788B2 (en) 2005-04-14
CZ293751B6 (en) 2004-07-14
RU2259199C2 (en) 2005-08-27
HUP0203139A2 (en) 2003-01-28
KR20020060201A (en) 2002-07-16
DE50003309D1 (en) 2003-09-18
ZA200203995B (en) 2003-10-29
BR0014922A (en) 2002-06-11
CN1382146A (en) 2002-11-27
HUP0203139A3 (en) 2004-12-28
NO20021846L (en) 2002-04-19

Similar Documents

Publication Publication Date Title
BE2018C008I2 (en)
CA2111851A1 (en) (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
YU11299A (en) Indasole derivatives
AP0102304A0 (en) Substituted indazole derivatives and related compounds.
AU5702996A (en) Oxygen-containing heterocyclic compounds
NZ301692A (en) Use of a compound which is both a beta adrenoreceptor antagonist and a alpha-1 adrenoreceptor antagonist especially carvedilol to treat congestive heart failure either on its own or with an angiotensin converting enzyme inhibitor, diuretic and/or cardiac glycoside
MXPA02003977A (en) INHIBITORS OF agr;L.
MXPA02004448A (en) Imidazopyridine derivatives as phosphodiesterase vii inhibitors.
ATE143019T1 (en) XANTHINE DERIVATIVES
AU6500298A (en) Derivatives of azetidine and pyrrolidine
CA2341890A1 (en) Oxygen-containing heterocyclic compounds
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
CA2388314A1 (en) Imidazole derivatives as phosphodiesterase vii inhibitors
CA2321188A1 (en) Derivatives of azetidine and pyrrolidine
PL340658A1 (en) Derivatives of biphenylamidine
AU554476B2 (en) Triazole derivatives
AU3709895A (en) Quinoline derivatives
IL160082A0 (en) Quinoline derivatives and use thereof as antitumor agents
EP0357403A3 (en) Substituted beta-diketones
EP1612211A4 (en) Novel carbapenem compounds
EP1595875A3 (en) Isothiocyanato-2,2-difluoro-1,3-benzodioxoles
IN190321B (en)
CA2273894A1 (en) Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use
ATE238300T1 (en) (3,4-DIHYDRO-2H-BENZO(1,4)OXAZINYL-METHYL)-3-(1 - INDOL-3-YL)-ALKYLAMINES
CA2378002A1 (en) Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131010